Eli Lil­ly bags an ear­ly-stage biotech for the neu­ro team — pay­ing $135M cash and of­fer­ing $1B-plus in mile­stones

Eli Lil­ly is snap­ping up a lit­tle Cam­bridge-based biotech to add to their neu­ro group.

The phar­ma gi­ant is get­ting Dis­arm Ther­a­peu­tics and its SARM1 in­hibitors for ax­on­al de­gen­er­a­tion, which has po­ten­tial to be used for pe­riph­er­al neu­ropa­thy, ALS and MS.

It’s cost­ing Lil­ly $135 mil­lion cash plus up to $1.225 bil­lion in mile­stones — if it all pays out. In re­turn, they’re get­ting a biotech that post­ed pre­clin­i­cal re­sults last fall, with a long haul ahead in the clin­ic.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.